Gi Innovation, Inc.
Clinical trials sponsored by Gi Innovation, Inc., explained in plain language.
-
New drug GI-108 aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (like lung, head and neck, pancreatic, or kidney cancer). The drug is designed to help the immune system fight cancer by targeting a protein called CD73 and delivering a modified immune s…
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
Can a drug combo turn back the clock on immune aging?
Disease control Recruiting nowThis early-stage study tests whether a combination of two experimental drugs, GI-102 and GIB-7, can improve immune function and other signs of aging in healthy adults and cancer survivors. The trial involves 15 participants and lasts 8 weeks, focusing on safety and changes in imm…
Phase: PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC